Samitas Konstantinos, Rådinger Madeleine, Bossios Apostolos
7th Respiratory Department and Asthma Centre, Athens Chest Hospital, Athens, Greece.
Recent Pat Antiinfect Drug Discov. 2011 Sep 1;6(3):189-205. doi: 10.2174/157489111796887855.
Peripheral blood eosinophilia and eosinophilic lung inflammation are common in a variety of pulmonary conditions, including eosinophilic pneumonia and asthma, hypereosinophilic syndrome and Churg-Strauss syndrome. Therapy in most of these clinical entities consists of long-term treatment with systemic corticosteroids, which is not always successful and has substantial side-effects. Interest has increased considerably regarding alternative corticosteroid-sparing "smart" regimens in these diseases that target IL-5, an important regulator of eosinophilic development and function. To date, two humanized monoclonal antibodies, mepolizumab and reslizumab, have been developed that bind to human IL-5. In addition a new monoclonal antibody (MEDI-563) has been recently developed targeting the IL-5 receptor. This review will investigate the current status on IL-5 targeted therapy and related patents regarding eosinophil-driven respiratory diseases, primarily eosinophilic asthma but also CSS and HES. Recent advances and information from clinical trials will be presented in a way that will allow the reader to approach the role of the eosinophil in the lung diseases presented in this review.
外周血嗜酸性粒细胞增多和嗜酸性粒细胞性肺部炎症在多种肺部疾病中很常见，包括嗜酸性粒细胞性肺炎和哮喘、高嗜酸性粒细胞综合征和Churg-Strauss综合征。大多数这些临床病症的治疗包括长期使用全身性皮质类固醇，这种治疗并不总是成功的，而且有很多副作用。针对这些疾病中替代皮质类固醇的“智能”方案的兴趣显著增加，这些方案靶向白细胞介素-5（IL-5），它是嗜酸性粒细胞发育和功能的重要调节因子。迄今为止，已经开发出两种与人类IL-5结合的人源化单克隆抗体，即美泊利单抗和瑞利珠单抗。此外，最近还开发了一种靶向IL-5受体的新型单克隆抗体（MEDI-563）。本综述将研究针对嗜酸性粒细胞驱动的呼吸系统疾病（主要是嗜酸性粒细胞性哮喘，但也包括CSS和HES）的IL-5靶向治疗的现状及相关专利。将以一种能让读者了解嗜酸性粒细胞在本综述中所呈现的肺部疾病中的作用的方式展示临床试验的最新进展和信息。
